Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

Inclusion Criteria: * Has the subject given written informed consent? * Is the subject between 18 years old and 80 years old inclusive? * Has the subject had histologically proven HGG with recurrence or progression following initial definitive therapy(s) such as surgery with or without adjuvant radiation therapy and/or chemotherapy (confirmed by diagnostic biopsy or contrast-enhanced MRI and evaluable by Macdonald criteria)? Note, if first recurrence of HGG is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field. * Does the patient have either (1) a single, enhancing tumor recurrence/progression that is ≤ 8 cm in greatest dimension, or (2) multiple enhancing tumor recurrences/progressions within the same surgical field where the sum of their greatest dimensions is ≤ 8 cm? * Based on the pre-operative evaluation, is the tumor recurrence/progression a candidate for ≥ 80% resection? * Has the subject elected not to undergo treatment with the Gliadel® wafer? * Does the subject have a Karnofsky performance status ≥ 70? * Does the subject have an absolute neutrophil count (ANC) ≥ 1500/mm3? * Does the subject have an absolute lymphocyte count ≥ 500/mm3? * Does the subject have a platelet count ≥ 100,000/mm3? * Does the subject have a Hgb ≥ 10 g/dL? * Does the subject have a coagulati…